In this regard, we reviewed relevant literature and found that EPN3 not only exerts oncogenic effects in NSCLC by regulating the EGFR signalling pathway but also exerts similar effects by activating the JAK1/2-STAT3 pathway [34]. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.